<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075491</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02566</org_study_id>
    <secondary_id>ID02-701</secondary_id>
    <secondary_id>R21CA097767</secondary_id>
    <secondary_id>CDR0000346722</secondary_id>
    <nct_id>NCT00075491</nct_id>
  </id_info>
  <brief_title>Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>A Phase II Evaluation With Correlative Studies Of Fenretinide (NSC 374551-4HPR) As A Single Agent In The Treatment Of Adult Patients With Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying how well neoadjuvant and adjuvant fenretinide
      works compared to adjuvant fenretinide alone in treating patients who are undergoing surgical
      resection for recurrent glioblastoma multiforme. Chemotherapy drugs, such as fenretinide,
      work in different ways to stop tumor cells from dividing so they stop growing or die. Giving
      chemotherapy before surgery may shrink the tumor so that it can be removed. Giving
      chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether
      neoadjuvant and adjuvant fenretinide is more effective than adjuvant fenretinide alone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the efficacy of neoadjuvant and adjuvant fenretinide vs adjuvant fenretinide
      alone, in terms of 6-month progression-free survival, in patients with recurrent glioblastoma
      multiforme undergoing surgical resection II. Correlate the serum and glioma tissue
      pharmacology of this drug with clinical response in patients treated with these regimens.

      III. Determine whether this drug induces apoptosis in glioma tissue in patients treated with
      these regimens.

      IV. Correlate the apoptotic index with tissue and serum concentration and clinical response
      in patients treated with these regimens.

      V. Compare radiological response, overall survival, and unexpected toxicity in patients
      treated with these regimens.

      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

      Arm I: Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo
      surgical resection.

      Arm II: Patients undergo surgical resection.

      Beginning two weeks after surgery, all patients receive adjuvant oral fenretinide twice daily
      on weeks 1 and 4. Courses repeat every 6 weeks in the absence of disease progression or
      unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 21-46 patients (10-23 per treatment arm) will be accrued for
      this study within 7-46 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.
  </why_stopped>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and tissue concentrations of fenretinide and its metabolite, 4-MPR using high-performance liquid chromatography (HPLC) assay</measure>
    <time_frame>At baseline, and at 1, 7, 14, and 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor apoptotic index after fenretinide treatment by immunohistochemistry</measure>
    <time_frame>At the time of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between tumor apoptotic index with serum and tissue fenretinide levels</measure>
    <time_frame>At the time of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of time to progression with drug levels and apoptotic index</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fenretinide effects on retinol, RBP, retinoid receptor levels and IGF-1</measure>
    <time_frame>Up to 21 days (course 1 and 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fenretinide activity using magnetic resonance spectroscopy (MRS)</measure>
    <time_frame>At the time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unexpected toxicity associated with fenretinide as assessed by CTC version 3.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (surgery)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenretinide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <other_name>fenretinimide</other_name>
    <other_name>McN-R-1967</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <arm_group_label>Arm II (surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <arm_group_label>Arm II (surgery)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <arm_group_label>Arm II (surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed glioblastoma multiforme after initial tumor resection

          -  Radiologically evident recurrent tumor after prior radiotherapy OR after treatment for
             no more than 2 prior relapses

               -  Enhancing or nonenhancing recurrent disease by MRI

          -  No progressive symptoms requiring urgent surgery

          -  Performance status - Karnofsky 70-100%

          -  More than 8 weeks

          -  Absolute granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  PT/PTT no greater than upper limit of normal

          -  SGPT no greater than 2.5 times normal

          -  Alkaline phosphatase no greater than 2.5 times normal

          -  Bilirubin less than 1.5 mg/dL

          -  BUN no greater than 1.5 times normal

          -  Creatinine no greater than 1.5 times normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for 2 months
             after study participation

          -  Amylase and lipase normal

          -  No active infection

          -  No other disease that would obscure toxicity or dangerously alter drug metabolism

          -  No other concurrent serious medical illness

          -  Not at risk from any study treatment delays

          -  Able to swallow fenretinide capsules

          -  Recovered from all prior chemotherapy

          -  Approximately 2 weeks since prior vincristine

          -  Approximately 6 weeks since prior nitrosoureas

          -  Approximately 3 weeks since prior procarbazine

          -  See Disease Characteristics

          -  At least 2 weeks since prior radiotherapy

          -  See Disease Characteristics

          -  At least 1 week since prior vitamin A

          -  At least 1 week since prior isotretinoin (AccutaneÂ®)

          -  No concurrent vitamin A during and for 2 weeks after study participation

          -  No concurrent antioxidants (e.g., ascorbic acid or vitamin E)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinay K. Puduvalli</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

